Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Name: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
License: Public Domain

Genelux Corporation

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

platinum

platinum-resistant ovarian cancer, platinum-refractory ovarian cancer, fallopian tube cancer, primary peritoneal cancer, high-grade serous ovarian cancer, endometrioid ovarian cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 172300
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.